Progressive supranuclear palsy (PSP) is a severe and rapidly progressing neurodegenerative disease that affects both motor and cognitive functions. Often misdiagnosed or underdiagnosed due to a lack of specific biomarkers, PSP has posed significant challenges for accurate diagnosis and treatment. However, a new study published in the journal Alzheimer’s & Dementia offers promising insights into this debilitating condition.